Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide vs Cyclophosphamide for Stem Cell Mobilization in Multiple Myeloma
NCT05517213Completed
- Sponsor
- Academy of Military Medical Sciences
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of etoposide in multiple myeloma (MM) (2 arms), sponsored by Academy of Military Medical Sciences. Primary endpoints: Mobilization Efficiency (CD34+ Cell Yield), Mobilization Failure Rate and 1 more. Started Sep 2022; status: completed.
02
Drugs
etoposide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05517213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517213.